# Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

> **NCT06081062** · PHASE3 · RECRUITING · sponsor: **ISU Abxis Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Fabry Disease

## Interventions

- **BIOLOGICAL:** Fabagal® (Agalsidase beta)
- **DRUG:** Active comparator (Agalsidase beta)

## Key facts

- **NCT ID:** NCT06081062
- **Lead sponsor:** ISU Abxis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-14
- **Primary completion:** 2025-06
- **Final completion:** 2025-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081062, "Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06081062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*